Follicular Lymphoma
News
Regimens produce similar results in FL
Rituximab plus lenalidomide had efficacy similar to that of rituximab plus chemotherapy in the treatment of follicular lymphoma (FL) in a phase 3...
News
Rituximab/lenalidomide similar to rituximab/chemotherapy for follicular lymphoma
Although the efficacy was similar, safety differed between the two regimens.
News
New BTK inhibitor under review in China
Zanubrutinib is being reviewed for treatment of relapsed/refractory mantle cell lymphoma.
News
EC approves CAR T-cell therapy for DLBCL, PMBCL
The European Commission (EC) has approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (Yescarta®) to treat two...
Article
First CAR T-cell therapy approvals bolster booming immunotherapy market
Article
Immunotherapies shape the treatment landscape for hematologic malignancies
News
Insurance status linked to survival in FL patients
Having health insurance can mean the difference between life and death for US patients with follicular lymphoma (FL), according to research...
News
Insurance is a matter of life or death for lymphoma patients
Improving patient access to affordable private insurance could improve survival outcomes for patients with follicular lymphoma.
News
Treatment improves PFS in early stage FL
A multidrug regimen can improve upon involved-field radiotherapy (IFRT) in patients with early stage follicular lymphoma (FL), according to...
News
Rituximab reduces risk of follicular lymphoma transformation
Rituximab-based chemotherapy and maintenance was associated with significantly lower risk of FL transformation from indolent to aggressive.